Compositions and methods for treatment of neurological disorders

Details Compositions and methods for treatment of neurological disorders Compositions and methods for treatment of neurological disorders

1997-09-05

2000-03-28

Reamer, James H.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514182, 514169, 514573, A61K 3705

Patent

active

060432241

ABSTRACT:
It has been discovered that the stimulation of .beta.-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising .beta.-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by .beta.-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E.sub.2 (PG E.sub.2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of .beta.-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E.sub.2, forskolin, or nicotine ditartrate is inhibited by immunosuppressants or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium/calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

REFERENCES:
patent: 4791099 (1988-12-01), Aroonsakul
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5348963 (1994-09-01), Gandy et al.
patent: 5614649 (1997-03-01), Iqbal et al.
Birge, J., Am. Geriatric. Soc., 44, 865, (1996).
McCarthy, et al., J. Cell Biol., 85, 890 (1980).
Peganini, et al., Am J. Epidemiol, 140, 256 (1994).
Mills, et al., J. Neurochem., 67, 1511 (1996).
Jaffe,et al., J. Biol. Chem., 269, 13065 (1994).
LeBlanc, J. Neurochem., 1183 (1997).
Cordell, Annu. Rev. Pharmacol. Toxicol., 34, 69 (1994).
LeBlanc, J. Neurochem., 2300, (1996).
Selkoe, Annu. Rev. Neurosci., 17, 489 (1994).
Lanrange, et al., Soc. Neursci. Abstr., 22, 378, (1996).
Nitsch,et al., Science, 258, 304 (1992).
Henderson, et al., Arch Neurol, 51, 896 (1994).
Wolf, et al., J. Biol. Chem., 270, 4916 (1995).
Thomlinson, (1992): In Greenfield's neuropathology (Adams, J.H. and Duchen L.W. eds.) pp. 1284-1410 Oxford University Press.
Caporaso, et al., Proc. Nat'l. Acad.Sci. U.S.A., 89, 3055 (1992).
Buxbaum, et al., Proc. Natl. Acad. Sci. U.S.A. . , 91, 4489 (1994).
Lee, et al., J. Neurochem. (supp), 69, S103B (1997).
Lee, et al., Proc. Natl. Acad. Sci. U.S.A., 92, 8083 (1995).
Lee, et al., Proc. Nat'l. Acad. Sci. U.S.A. . , 94, 5422 (1997).
Ulus and Wurtman , J. Pharm. Exp. Ther., 281, 149 (1997).
Buxbaum, et al., Proc. Nat'l Acad. Sci. U.S.A., 89, 10075 (1992).
Rich, et al. Neurology, 45, 51 (1995).
Anderson, et al., Neurology, 45, 1441 (1995).
McGeer, et al., Lancet, 335, 1037 (1990).
Nordstedt, et al., Proc. Natl. Acad. Sci. U.S.A., 88, 8910 (1991).
Anderson, et al., EMBO J., 8, 3627 (1989).
Neve, et al., Neuron, 1, 669 (1990).
Golde, et al., Neuron, 4, 253 (1990).
Lindsay, et al., Neurology, 44, 2073 (1994).
Moran, et al., Proc. Natl. Acad. Sci. U.S.A., 92, 5341 (1995).
Rodgers, et al., Neurology, 43 1609 (1993).
Hsiao, et al., Neuron, 15, 1203-1218 (1995).
Siman, et al., J.Neuron., 3, 275 (1989).
Maruyama, et al., Nature, 347, 566 (1990).
Banati, et al., Cereb. Blood Flow Metab., 15, 647 (1995).
Kozlowski, et al., J. Neurosci, 12, 1679 (1992).
Brun, et al., Neuodegeneration, 4, 171 (1995).
Yankner, et al., Science, 245, 417 (1989).
Eftimiopoulos, et al., J. Neurochem., 67, 872 (1996).
Caporaso, et al., Proc. Nat'l Acad. Sci. U.S.A., 89, 2225 (1992).
Lee, et al., J. Neurochem., 68, 1830 (1997).

Affiliated with

Also associated with

Rating

Compositions and methods for treatment of neurological disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for treatment of neurological disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of neurological disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1326143